← FDA DRUG APPROVALS

FDA ANDA · ANDA210081

BUPROPION HYDROCHLORIDE

Sponsor: TWI PHARMS

APPLICATION
ANDA210081
TYPE
ANDA
ORIGINAL APPROVAL
2017-11-03
LATEST ACTION
2025-01-22
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
Discontinued

Products

BUPROPION HYDROCHLORIDEDiscontinued
BUPROPION HYDROCHLORIDE 300MG · TABLET, EXTENDED RELEASE · ORAL
BUPROPION HYDROCHLORIDEDiscontinued
BUPROPION HYDROCHLORIDE 150MG · TABLET, EXTENDED RELEASE · ORAL

Approval history

2025-01-22Labeling · Supplement 19 · standardAP
2023-02-07Labeling · Supplement 16 · standardAP
2023-02-07Labeling · Supplement 11 · standardAP
2017-11-03UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →